pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
cullgen PRESS RELEASE ARCHIVE
Jul 27, 2023
Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients
Jun 15, 2023
Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders
May 8, 2023
Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund
Aug 11, 2022
Cullgen Announces Chinese NMPA Allowance of Investigational New Drug Application of TRK Degrader to Begin Clinical Trials
Jun 17, 2021
Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer
Jun 10, 2021
Cullgen Appoints Dr. Mark Deeg to Lead Clinical Development
Feb 25, 2021
Cullgen Closes $50 Million Series B Investment to Advance Targeted Protein Degraders and Novel E3 Ligands Platform
Oct 16, 2020
Cullgen Announces “Featured Article” Publication of First in Class TRK Protein Degraders in Journal of Medicinal Chemistry
Apr 7, 2020
Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in Journal of Medicinal Chemistry
Apr 10, 2019
Cullgen Receives $16 Million Series A Investment to Advance Pipeline of Targeted Protein Degraders
Jul 18, 2018
Cullgen Announces Expanded Scientific Advisory Board
Apr 2, 2018
Cullgen Announces ALK PROTACs Publication by Its Co-founders in the European Journal of Medicinal Chemistry
Mar 1, 2018
Cullgen Announces Series Seed Financing
